Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EP-026856
- Development stage
- Preclinical
- Lead developer
- Enanta Pharmaceuticals
- Modality
- Small Molecules
01
Overview
EP-026856 is a small molecule inhibitor of Apoptosis signal-regulating kinase 1 (ASK1), developed by Enanta Pharmaceuticals. ASK1 is a member of the mitogen-activated protein kinase kinase kinase (MAP3K) family that is activated by various stressors, including oxidative stress and inflammation, leading to the activation of JNK and p38 signaling pathways. By inhibiting ASK1, EP-026856 aims to reduce apoptosis, inflammation, and fibrosis. The compound is currently in preclinical development, primarily targeting digestive system-related conditions such as non-alcoholic steatohepatitis (NASH) or other inflammatory liver diseases.
02
Targets
MAP3K5 (ASK1)
Beyond the preview
Go deeper on EP-026856.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EP-026856.